RESUMO
In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent).
Assuntos
Aprovação de Drogas , Anticorpos Monoclonais/uso terapêutico , Azetidinas/uso terapêutico , Compostos de Benzil/uso terapêutico , Carbamatos/uso terapêutico , Clobetasol/análogos & derivados , Clobetasol/uso terapêutico , Combinação de Medicamentos , Fumarato de Formoterol/uso terapêutico , Compostos Heterocíclicos com 3 Anéis/uso terapêutico , Humanos , Lamivudina/uso terapêutico , Ácidos Nicotínicos/uso terapêutico , Oxazinas , Fenilalanina/análogos & derivados , Fenilalanina/uso terapêutico , Piperazinas , Pregnanolona/uso terapêutico , Piridonas , Tropanos/uso terapêutico , Estados Unidos , United States Food and Drug Administration , beta-Ciclodextrinas/uso terapêuticoRESUMO
College students who participate in semester abroad programs have diverse but positive experiences. Variables such as the educational institution attended by the students and the location of the study abroad can affect the experiences of the students. There is minimal research concerning students from Christian colleges who study abroad. The purpose of this study was to investigate the lived experiences of college students participating in a semester abroad program in a developing country. Seven college students were interviewed regarding their experiences by three senior nursing students who also participated in the study abroad program. Results indicated that major factors influencing students' experiences were related to cultural immersion, role relationships, challenges encountered, and personal growth. Students reported that relationships with people and faith in Christ were strengthened through the experience.
